The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) demonstrated the potential ability of IL-1β and pro-inflammatory cytokine targeting to reduce vascular end points, including the rate of recurrent cardiovascular events, such as nonfatal myocardial infarction, nonfatal stroke, and cardiovascular mortality, among patients with myocardial infarction and elevated circulating CRP levels (14). The gene discussed is CRP; the disease is stroke disorder.